These findings contribute to the understanding of the mechanisms by which EGFR-driven signaling networks control YAP/TAZ activation in normal cells and cancer, and support the therapeutic potential of inhibiting YAP/TAZ function in patients with cancers harboring EGFR alterations to enhance the response to EGFR targeted therapies, and prevent emergence of drug resistance. The gene discussed is EGFR; the disease is cancer.